Related Experiment Video
Updated: May 21, 2026
12:28
Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
Published on: January 11, 2019
Non-apoptotic routes to defeat cancer
Jennifer L Guerriero1, Dara Ditsworth, Wei-Xing Zong
1Department of Molecular Genetics & Microbiology; Stony Brook University; Stony Brook, NY USA.
Oncoimmunology
|June 22, 2012
Abstract:
The mechanism of tumor cell death after treatment with DNA alkylating agents in vivo previously remained largely unknown. We demonstrate that tumor regression after chemotherapy occurs via sporadic necrosis and relies on activation of innate immunity in a manner dependent on high mobility group box 1 protein (HMGB1).
Insights
Chemotherapy triggers tumor cell death through necrosis, activating the innate immune system. This process depends on high mobility group box 1 protein (HMGB1) for tumor regression.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- The precise mechanisms of tumor cell death following DNA alkylating agent chemotherapy in vivo are not fully understood.
- Understanding these mechanisms is crucial for improving cancer treatment efficacy.
Purpose of the Study:
- To elucidate the mechanism of tumor cell death induced by DNA alkylating agents in a living organism.
- To investigate the role of innate immunity and high mobility group box 1 protein (HMGB1) in chemotherapy-induced tumor regression.
Main Methods:
- In vivo studies utilizing DNA alkylating agents for chemotherapy.
- Analysis of tumor cell death pathways, focusing on necrosis.
- Assessment of innate immune system activation.
- Investigation of the involvement of high mobility group box 1 protein (HMGB1).
Main Results:
- Tumor regression following chemotherapy occurs through a process of sporadic necrosis.
- The activation of the innate immune system is essential for this tumor regression.
- High mobility group box 1 protein (HMGB1) plays a critical role in mediating the innate immune response during chemotherapy.
Conclusions:
- Chemotherapy-induced tumor regression is mediated by necrosis and relies on innate immune activation.
- High mobility group box 1 protein (HMGB1) is a key mediator linking tumor cell death to innate immunity activation in vivo.
- These findings provide new insights into the interplay between chemotherapy, cell death, and immune responses in cancer treatment.
More Related Videos
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
01:17The Extrinsic Apoptotic Pathway
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...